查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1597805

緩釋性注射劑市場：按劑量、給藥途徑和最終用戶 - 2025-2030 年全球預測

Sustained Release Injectables Market by Dosage (In Situ Forming Formulations, In Situ Forming Gel System, In Situ Forming Microparticle Systems), Route of Administration (Interarterial, Intracardiac, Intradermal), End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年緩釋性注射劑市場規模為21.5億美元，預計2024年將達22.9億美元，複合年成長率為6.95%，2030年將達34.5億美元。

緩釋性注射劑是製藥業的重要組成部分，專注於在較長時間內逐漸釋放藥物的製劑，從而提高患者的依從性和治療結果。這些注射劑在慢性疾病的治療中極為重要，其穩定的藥物釋放減少了給藥頻率並提高了患者的依從性。主要應用涵蓋腫瘤學、內分泌學和神經學等治療領域。慢性病盛行率的上升、藥物傳輸技術的進步以及對便捷治療方法的日益偏好推動了該市場的發展。另一個重大機會是快速成長的老年人口，他們需要易於管理的長期藥物解決方案。創新研究旨在開發用於藥物封裝的生物分解性聚合物，可顯著提高藥物傳輸系統的安全性和效率。然而，新興市場面臨高昂的開發成本和嚴格的監管要求等限制，阻礙了成長。此外，潛在的副作用和配方的複雜性也帶來了挑戰。儘管有這些挑戰，市場仍充滿機會。鼓勵公司投資於新型生物分解性材料和奈米技術整合的研究，這些研究有可能徹底改變控制釋放機制。與學術機構的合作可以在推動創新方面取得豐碩成果，同時確保遵守監管標準。市場競爭日益激烈，由於技術進步和市場滲透，策略聯盟和合併不斷增加。北美仍然是迄今為止最強大的，擁有先進的醫療基礎設施和大量的研發投資。然而，由於醫療保健系統的改善和對先進療法的需求不斷成長，亞太地區的新興市場仍具有開拓的潛力。總之，緩釋性注射劑代表了一個充滿活力的市場，具有巨大的成長潛力，需要策略創新和嚴格的監管環境才能成功擴張。

主要市場統計
基準年[2023] 21.5億美元
預測年份 [2024] 22.9億美元
預測年份 [2030] 34.5億美元
複合年成長率（%） 6.95%

市場動態：快速發展的注射緩釋性市場的關鍵市場洞察

供需的動態交互作用正在改變緩釋性注射劑市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 不良生活習慣導致主要慢性病盛行率上升
    • 兒童和老年人對緩釋性注射劑的需求不斷增加
    • 注射劑比口服藥物具有更高的生物利用度
  • 市場限制因素
    • 填充過程中的流變變化、長期儲存過程中的不穩定、釋放速率無法調節
  • 市場機會
    • 奈米技術、微米化和穩定製程等技術進步
    • 天然和化學合成的生物分解性材料簡介
  • 市場挑戰
    • 藥品成本上漲和熟練專家短缺

波特的五力：駕馭緩釋性注射劑市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解緩釋性注射劑市場的外部影響

外部宏觀環境因素在塑造緩釋性注射劑市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解緩釋性注射劑市場競爭狀況

對緩釋性注射劑市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣緩釋性注射劑市場供應商的績效評估

FPNV定位矩陣是評估緩釋性注射劑市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，描繪緩釋性注射劑市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對緩釋性注射劑市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告提供了涵蓋關鍵重點領域的市場全面分析：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 不健康的生活習慣日益增多，導致主要慢性疾病的盛行率增加
      • 小兒科和老年醫學對緩釋性注射劑的需求不斷增加
      • 注射劑比口服藥物有更好的生物利用度
    • 抑制因素
      • 填充過程中的流變變化、長期儲存過程中的不穩定、釋放速率不可調
    • 機會
      • 奈米技術、微米化和穩定製程等技術進步
      • 天然和化學合成的生物分解性材料簡介
    • 任務
      • 藥品價格高且缺乏熟練的專業人員
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章緩釋性注射劑市場按劑量

  • 原位發泡配方
  • 原位形成凝膠系統
  • 原位形成微粒系統
  • 脂質體
  • 微膠囊
  • 微球
  • 高分子奈米微胞

第7章緩釋性注射劑市場：依給藥途徑

  • 動脈之間
  • 心內的
  • 皮內
  • 肌肉注射
  • 靜脈
  • 皮下的

第8章緩釋性注射劑市場：依最終用戶分類

  • 診斷實驗室
  • 醫院
  • 專科診所

第9章美洲緩釋性注射劑市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太緩釋性注射劑市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲/中東/非洲緩釋性注射劑市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭場景分析
  • 戰略分析和建議

公司名單

  • Dr. Reddy's Laboratories
  • GP Pharm SA
  • Innocore Pharmaceuticals
  • Janssen Pharmaceutical Companies by Johnson & Johnson
  • Novartis AG
  • Oakwood Laboratories
  • Pacira Pharmaceuticals, Inc.
  • PhaseBio Pharmaceuticals, Inc
  • Taiwan Liposome Company（TLC）
  • ViiV Healthcare
  • Xbrane Biopharma AB
Product Code: MRR-43078BB92C8D

The Sustained Release Injectables Market was valued at USD 2.15 billion in 2023, expected to reach USD 2.29 billion in 2024, and is projected to grow at a CAGR of 6.95%, to USD 3.45 billion by 2030.

Sustained Release Injectables are a pivotal segment within the pharmaceutical industry, focusing on formulations that allow for the gradual release of medication over an extended period, thereby improving patient compliance and therapeutic outcomes. These injectables are crucial in treating chronic conditions, offering a steady drug release that reduces the frequency of administration and enhances patient adherence. Key applications span across therapeutic areas such as oncology, endocrinology, and neurology. The market is fueled by the rising prevalence of chronic diseases, advancements in drug delivery technologies, and a growing preference for convenient treatment regimens. A significant opportunity lies in the burgeoning geriatric population who require manageable long-term medication solutions. Innovative research is directed towards developing biodegradable polymers for drug encapsulation, which can significantly enhance the safety and efficiency of drug delivery systems. However, the market faces limitations such as the high cost of development and stringent regulatory requirements, which can impede growth. Additionally, potential adverse reactions and the complexity of formulation pose challenges. Despite these challenges, the market is rife with opportunities. Companies are recommended to invest in research focused on novel biodegradable materials and Nanotechnology integration, which could revolutionize controlled release mechanisms. Collaborations with academic institutions could prove fruitful in driving innovation while ensuring compliance with regulatory standards. The market is increasingly competitive, fostering a surge in strategic alliances and mergers to leverage technological advancements and market penetration. North America remains a dominant player due to its sophisticated healthcare infrastructure and substantial investment in R&D. However, emerging markets in Asia-Pacific present untapped potential given their improving healthcare systems and growing demand for advanced therapeutics. In conclusion, sustained release injectables embody a dynamic market with significant growth potential, demanding strategic innovation and diligent navigation of regulatory landscapes for successful business expansion.

KEY MARKET STATISTICS
Base Year [2023] USD 2.15 billion
Estimated Year [2024] USD 2.29 billion
Forecast Year [2030] USD 3.45 billion
CAGR (%) 6.95%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Sustained Release Injectables Market

The Sustained Release Injectables Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of major chronic diseases due to increasing adoption of poor lifestyle habits
    • Rise in demand for paediatric and geriatric sustained release injectables
    • Injectable preparations have a better bioavailability than oral preparations
  • Market Restraints
    • Rheological changes during filling, instability on long-term storage and nonadjustable release rate
  • Market Opportunities
    • Advancement in technology such as nanotechnology, micronation, and stabilization process
    • Introduction of natural and chemosynthetic biodegradable materials
  • Market Challenges
    • High cost of drugs and lack of skilled professionals

Porter's Five Forces: A Strategic Tool for Navigating the Sustained Release Injectables Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Sustained Release Injectables Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Sustained Release Injectables Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Sustained Release Injectables Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Sustained Release Injectables Market

A detailed market share analysis in the Sustained Release Injectables Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Sustained Release Injectables Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Sustained Release Injectables Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Sustained Release Injectables Market

A strategic analysis of the Sustained Release Injectables Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Sustained Release Injectables Market, highlighting leading vendors and their innovative profiles. These include Dr. Reddy's Laboratories, GP Pharm S.A., Innocore Pharmaceuticals, Janssen Pharmaceutical Companies by Johnson & Johnson, Novartis AG, Oakwood Laboratories, Pacira Pharmaceuticals, Inc., PhaseBio Pharmaceuticals, Inc, Taiwan Liposome Company (TLC), ViiV Healthcare, and Xbrane Biopharma AB.

Market Segmentation & Coverage

This research report categorizes the Sustained Release Injectables Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Dosage, market is studied across In Situ Forming Formulations, In Situ Forming Gel System, In Situ Forming Microparticle Systems, Liposome, Microcapsule, Microsphere, and Polymeric Micelles.
  • Based on Route of Administration, market is studied across Interarterial, Intracardiac, Intradermal, Intramuscular, Intravenous, and Subcutaneous.
  • Based on End-User, market is studied across Diagnostic Laboratories, Hospitals, and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of major chronic diseases due to increasing adoption of poor lifestyle habits
      • 5.1.1.2. Rise in demand for paediatric and geriatric sustained release injectables
      • 5.1.1.3. Injectable preparations have a better bioavailability than oral preparations
    • 5.1.2. Restraints
      • 5.1.2.1. Rheological changes during filling, instability on long-term storage and nonadjustable release rate
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancement in technology such as nanotechnology, micronation, and stabilization process
      • 5.1.3.2. Introduction of natural and chemosynthetic biodegradable materials
    • 5.1.4. Challenges
      • 5.1.4.1. High cost of drugs and lack of skilled professionals
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Sustained Release Injectables Market, by Dosage

  • 6.1. Introduction
  • 6.2. In Situ Forming Formulations
  • 6.3. In Situ Forming Gel System
  • 6.4. In Situ Forming Microparticle Systems
  • 6.5. Liposome
  • 6.6. Microcapsule
  • 6.7. Microsphere
  • 6.8. Polymeric Micelles

7. Sustained Release Injectables Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Interarterial
  • 7.3. Intracardiac
  • 7.4. Intradermal
  • 7.5. Intramuscular
  • 7.6. Intravenous
  • 7.7. Subcutaneous

8. Sustained Release Injectables Market, by End-User

  • 8.1. Introduction
  • 8.2. Diagnostic Laboratories
  • 8.3. Hospitals
  • 8.4. Specialty Clinics

9. Americas Sustained Release Injectables Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Sustained Release Injectables Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Sustained Release Injectables Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Dr. Reddy's Laboratories
  • 2. GP Pharm S.A.
  • 3. Innocore Pharmaceuticals
  • 4. Janssen Pharmaceutical Companies by Johnson & Johnson
  • 5. Novartis AG
  • 6. Oakwood Laboratories
  • 7. Pacira Pharmaceuticals, Inc.
  • 8. PhaseBio Pharmaceuticals, Inc
  • 9. Taiwan Liposome Company (TLC)
  • 10. ViiV Healthcare
  • 11. Xbrane Biopharma AB

LIST OF FIGURES

  • FIGURE 1. SUSTAINED RELEASE INJECTABLES MARKET RESEARCH PROCESS
  • FIGURE 2. SUSTAINED RELEASE INJECTABLES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. SUSTAINED RELEASE INJECTABLES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. SUSTAINED RELEASE INJECTABLES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. SUSTAINED RELEASE INJECTABLES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. SUSTAINED RELEASE INJECTABLES MARKET DYNAMICS
  • TABLE 7. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY IN SITU FORMING FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY IN SITU FORMING GEL SYSTEM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY IN SITU FORMING MICROPARTICLE SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY LIPOSOME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY MICROCAPSULE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY MICROSPHERE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMERIC MICELLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY INTERARTERIAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY INTRACARDIAC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY INTRADERMAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 46. ASIA-PACIFIC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 50. AUSTRALIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 51. AUSTRALIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 52. AUSTRALIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 53. CHINA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 54. CHINA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 55. CHINA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. INDIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 57. INDIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 58. INDIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. INDONESIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 60. INDONESIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 61. INDONESIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 62. JAPAN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 63. JAPAN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 64. JAPAN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. MALAYSIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 66. MALAYSIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 67. MALAYSIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 68. PHILIPPINES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 69. PHILIPPINES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 70. PHILIPPINES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. SINGAPORE SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 72. SINGAPORE SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 73. SINGAPORE SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 74. SOUTH KOREA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 75. SOUTH KOREA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 76. SOUTH KOREA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. TAIWAN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 78. TAIWAN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 79. TAIWAN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 80. THAILAND SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 81. THAILAND SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 82. THAILAND SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. VIETNAM SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 84. VIETNAM SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 85. VIETNAM SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 90. DENMARK SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 91. DENMARK SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 92. DENMARK SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. EGYPT SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 94. EGYPT SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 95. EGYPT SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 96. FINLAND SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 97. FINLAND SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 98. FINLAND SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. FRANCE SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 100. FRANCE SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 101. FRANCE SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 102. GERMANY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 103. GERMANY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 104. GERMANY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 105. ISRAEL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 106. ISRAEL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 107. ISRAEL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 108. ITALY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 109. ITALY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 110. ITALY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 111. NETHERLANDS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 112. NETHERLANDS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 113. NETHERLANDS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. NIGERIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 115. NIGERIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 116. NIGERIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 117. NORWAY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 118. NORWAY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 119. NORWAY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 120. POLAND SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 121. POLAND SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 122. POLAND SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 123. QATAR SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 124. QATAR SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 125. QATAR SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 126. RUSSIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 127. RUSSIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 128. RUSSIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 129. SAUDI ARABIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 130. SAUDI ARABIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 131. SAUDI ARABIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 132. SOUTH AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 133. SOUTH AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 134. SOUTH AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 135. SPAIN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 136. SPAIN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 137. SPAIN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. SWEDEN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 139. SWEDEN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 140. SWEDEN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 141. SWITZERLAND SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 142. SWITZERLAND SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 143. SWITZERLAND SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 144. TURKEY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 145. TURKEY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 146. TURKEY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED ARAB EMIRATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 148. UNITED ARAB EMIRATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 149. UNITED ARAB EMIRATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 150. UNITED KINGDOM SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 151. UNITED KINGDOM SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 152. UNITED KINGDOM SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 153. SUSTAINED RELEASE INJECTABLES MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 154. SUSTAINED RELEASE INJECTABLES MARKET, FPNV POSITIONING MATRIX, 2023